10 November 2020
New study suggests that having COVID-19 increases a person’s risk of developing psychiatric disorders, and that having a psychiatric disorder increases the chance of getting COVID-19.
- Almost 1 in 5 people diagnosed with COVID-19 receive a psychiatric diagnosis within the next 3 months
- 1 in 4 of these people had not had a psychiatric diagnosis before COVID-19
- Patients with existing psychiatric disorders might be more likely to get COVID-19
Researchers at the University of Oxford, Department of Psychiatry and NIHR Oxford Health Biomedical Research Centre, report the first large-scale evidence that COVID-19 survivors are at an increased risk of psychiatric disorders. The study, published in The Lancet Psychiatry, used the TriNetX electronic health records of 69 million people in the USA including over 62,000 cases of COVID-19.
In the 3 months following testing positive for COVID-19, 1 in 5 survivors were found to get a diagnosis of anxiety, depression, or insomnia, for the first time. This is about twice as likely as for other groups of patients over the same period. A diagnosis of dementia may also be commoner. COVID-19 was also associated with more new psychiatric diagnoses in people who already had a history of psychiatric problems. Overall, almost 20 per cent of people received a psychiatric diagnosis within 90 days of getting COVID-19.
Paul Harrison, Professor of Psychiatry, University Oxford, Theme Lead - NIHR Oxford Health BRC, who led the study, commented ‘People have been worried that COVID-19 survivors will be at greater risk of mental health problems, and our findings in a large and detailed study show this to be likely. Services need to be ready to provide care, especially since our results are likely to be underestimates of the actual number of cases. We urgently need research to investigate the causes and identify new treatments.’
The researchers also found that people with a pre-existing psychiatric diagnosis were 65 per cent more likely to be diagnosed with COVID-19 than those without, even when the known risk factors for COVID-19 were taken into account.
Dr Max Taquet, NIHR Academic Clinical Fellow, who conducted the analyses, remarked, ‘This finding was unexpected and needs investigation. In the meantime, having a psychiatric disorder should be added to the list of risk factors for COVID-19.’
This study was supported by the NIHR Oxford Health Biomedical Research Centre.
Notes to editors
For further information, please contact: Genevieve Juillet, Media Relations Manager (Research and Innovation), University of Oxford, firstname.lastname@example.org
Full paper: Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62,354 COVID-19 cases in the USA, The Lancet Psychiatry. http://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(20)30462-4/fulltext .
The University of Oxford
Oxford University has been placed number 1 in the Times Higher Education World University Rankings for the fifth year running, and at the heart of this success is our ground-breaking research and innovation. Oxford is world-famous for research excellence and home to some of the most talented people from across the globe. Our work helps the lives of millions, solving real-world problems through a huge network of partnerships and collaborations. The breadth and interdisciplinary nature of our research sparks imaginative and inventive insights and solutions.
The Department of Psychiatry at the University of Oxford’s mission is to conduct world-class research, teach psychiatry to medical students, develop future researchers in a graduate programme, teach doctors in training, promote excellence in clinical practice, and develop and provide innovative clinical services. It supports research in four key areas: neurobiology, psychological treatments, developmental psychiatry and social psychiatry. The Department is committed to the translation of scientific discovery into benefits for patients. www.psych.ox.ac.uk
The NIHR Oxford Health Biomedical Research Centre is a partnership between the Oxford Health NHS Foundation Trust and the University of Oxford. We aim to bring the best science to the complex problems of mental health and dementia. www.oxfordhealthbrc.nihr.ac.uk
TriNetX is the global health research network that connects the world of drug discovery and development from pharmaceutical company to study site, and investigator to patient by sharing real-world data to make clinical and observational research easier and more efficient. TriNetX combines real time access to longitudinal clinical data with state-of-the-art analytics to optimize protocol design and feasibility, site selection, patient recruitment, and enable discoveries through the generation of real-world evidence. The TriNetX platform is HIPAA and GDPR compliant. For more information, visit TriNetX at www.trinetx.com or follow @TriNetX on Twitter.
Funding for the University of Oxford’s coronavirus research is crucial to the development of a vaccine and the subsequent delivery of effective drugs to combat this new virus. Unprecedented speed, scope and ambition is required. Please make a gift. Any gift made will help contribute to the fight against coronavirus.
Oxford Health NHS Foundation Trust (OHFT) and Oxford Health NHS Foundation Trust (OHFT) provides physical, mental health and social care for people of all ages across Oxfordshire, Buckinghamshire, Swindon, Wiltshire, Bath and North East Somerset. Our services are delivered at community bases, hospitals, clinics and people’s homes. We focus on delivering care as close to home as possible. As a leading teaching, training and research trust, we have close links to Oxford and Oxford Brookes, Buckinghamshire, Reading and Bath universities. We are part of the Oxford Academic Health Science Centre, working closely with our university colleagues to translate their findings into clinical care as quickly as possible, enabling people using our services to benefit from the latest advances in healthcare.
We host the NIHR Oxford Health Biomedical Research Centre with Oxford University, and aim to bring the best science to the complex problems of mental disorders and dementia. We also host the Collaboration for Leadership in Applied Health Research and Care (CLAHRC) Oxford; a partnership between universities, healthcare commissioners and providers, charities and industry targeting health and social care problems in Oxfordshire and the Thames Valley. www.oxfordhealth.nhs.uk
The National Institute for Health Research (NIHR) is the nation's largest funder of health and care research. The NIHR:
- Funds, supports and delivers high quality research that benefits the NHS, public health and social care
- Engages and involves patients, carers and the public in order to improve the reach, quality and impact of research
- Attracts, trains and supports the best researchers to tackle the complex health and care challenges of the future
- Invests in world-class infrastructure and a skilled delivery workforce to translate discoveries into improved treatments and services
- Partners with other public funders, charities and industry to maximise the value of research to patients and the economy
The NIHR was established in 2006 to improve the health and wealth of the nation through research, and is funded by the Department of Health and Social Care. In addition to its national role, the NIHR supports applied health research for the direct and primary benefit of people in low- and middle-income countries, using UK aid from the UK government.